Lupin names new U.S. specialty president amid Solosec launch
Lupin is looking to a longtime commercial operations and specialty veteran to head up its US specialty business unit. The Mumbai, India-based company has named Nicholas Hart to the role of president of specialty for its U.S. organization, overseeing the specialty brand operations’ growth strategy, P&L and organization.
Hart, who has more than 25 years of experience in the industry, joins Lupin from Ferring Pharmaceuticals, where he was head of the company’s reproductive health business unit. Before Ferring, Hart was senior vice president of sales and marketing at URL Pharma. His industry experience has included roles in commercial operations, corporate strategy and business development, Lupin said.
Hart joins the company as Lupin launches its recently approved bacterial vaginosis treatment Solosec. The product is the first new oral antibiotic for the ailment that affects roughly 21 million people between the ages of 14 and 49 every year.
[caption id="attachment_588755" align="alignright" width="150"]
Nicholas Hart[/caption]
“We are delighted to welcome Nick to Lupin at a crucial time as we prepare to launch Solosec in the U.S. market and accelerate efforts to build our specialty business,” Lupin CEO Vinita Gupta said. His knowledge and experience in the industry will be valuable for our growth aspirations in the U.S. market.”
Solosec was developed by Symbiomix Therapeutics and gained Food and Drug Administration approval in September. Lupin acquired Symbiomix less than a month after Solosec’s approval in a move that strengthened the company’s gynecological pipeline.
“With more than four million women treated for BV in the United States annually, and only 50% completing 5-to-7-day treatments, there is a clear need for an effective, single-dose oral treatment,” Gupta said. “We are proud that Lupin has been at the forefront of advancing safe and affordable healthcare for women globally for decades, and we are committed to helping prevent and manage women’s health conditions with serious consequences, including BV.”
Hart, who has more than 25 years of experience in the industry, joins Lupin from Ferring Pharmaceuticals, where he was head of the company’s reproductive health business unit. Before Ferring, Hart was senior vice president of sales and marketing at URL Pharma. His industry experience has included roles in commercial operations, corporate strategy and business development, Lupin said.
Hart joins the company as Lupin launches its recently approved bacterial vaginosis treatment Solosec. The product is the first new oral antibiotic for the ailment that affects roughly 21 million people between the ages of 14 and 49 every year.
[caption id="attachment_588755" align="alignright" width="150"]
Nicholas Hart[/caption]“We are delighted to welcome Nick to Lupin at a crucial time as we prepare to launch Solosec in the U.S. market and accelerate efforts to build our specialty business,” Lupin CEO Vinita Gupta said. His knowledge and experience in the industry will be valuable for our growth aspirations in the U.S. market.”
Solosec was developed by Symbiomix Therapeutics and gained Food and Drug Administration approval in September. Lupin acquired Symbiomix less than a month after Solosec’s approval in a move that strengthened the company’s gynecological pipeline.
“With more than four million women treated for BV in the United States annually, and only 50% completing 5-to-7-day treatments, there is a clear need for an effective, single-dose oral treatment,” Gupta said. “We are proud that Lupin has been at the forefront of advancing safe and affordable healthcare for women globally for decades, and we are committed to helping prevent and manage women’s health conditions with serious consequences, including BV.”